SCHEMBL2394851

SCHEMBL2394851

FC(F)(F)Oc1ccc(Cn2cnnc2-c2ccc3[nH]cnc3c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 6/20 0.64
MET P08581 1/20 0.39
SCN5A Q14524 1/20 0.37
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
PGGT1B P53609 1/20 0.36
TYMS P04818 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
HSD17B13 Q7Z5P4 2/20 0.35
P2RX7 Q99572 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
IDO1 P14902 1/20 0.34
QPCT Q16769 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398000 0.86 QPCTL (0.84) QPCTLMETP2RX7QPCT
SCHEMBL2396993 0.85 QPCTL (0.69) QPCTLFNTAFNTBPGGT1BP2RX7
SCHEMBL2398286 0.85 QPCTL (0.62) QPCTLMETP2RX7PRMT5WDR77
SCHEMBL2399121 0.84 QPCTL (0.85) QPCTLP2RX7PRMT5WDR77QPCT
SCHEMBL2399845 0.84 QPCTL (0.63) QPCTLP2RX7PRMT5WDR77QPCT
SCHEMBL2398147 0.84 QPCTL (0.66) QPCTLPRMT5WDR77IDO1QPCT
SCHEMBL2397290 0.82 QPCTL (0.68) QPCTLP2RX7PRMT5WDR77QPCT
SCHEMBL2395959 0.81 QPCTL (0.66) QPCTLP2RX7PRMT5WDR77QPCT
SCHEMBL2396775 0.81 QPCTL (0.57) QPCTLPRMT5WDR77QPCT
SCHEMBL2395188 0.81 QPCTL (0.59) QPCTLP2RX7PRMT5WDR77QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP claimed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US claimed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
WO-2011107530-A2 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS QPCTL 5/4885MET 4197/4885SCN5A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.